Klaus Bendtzen

Research interests

Publications

• Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

  Gut · 2013 · https://doi.org/10.1136/gutjnl-2013-305279

• Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management

  Annals of Medicine · 2010 · https://doi.org/10.3109/07853890903559724

• Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

  Scandinavian Journal of Gastroenterology · 2010 · https://doi.org/10.3109/00365521.2010.536254

• Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

  Annals of the Rheumatic Diseases · 2008 · https://doi.org/10.1136/ard.2008.092833

• T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis

  Immunology · 2008 · https://doi.org/10.1111/j.1365-2567.2008.02837.x

• Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease

  The American Journal of Gastroenterology · 2007 · https://doi.org/10.1111/j.1572-0241.2007.01638.x

• Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

  Lara D. Veeken · 2007 · https://doi.org/10.1093/rheumatology/kem261

• Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case–control study nested in a cohort of Norwegian blood donors

  Annals of the Rheumatic Diseases · 2007 · https://doi.org/10.1136/ard.2007.073825

• Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab

  Arthritis & Rheumatism · 2006 · https://doi.org/10.1002/art.22214

• Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

  Neurology · 2005 · https://doi.org/10.1212/01.wnl.0000166049.51502.6a

• Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

  The Lancet · 2003 · https://doi.org/10.1016/s0140-6736(03)14541-2

• Serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease

  Diabetologia · 2002 · https://doi.org/10.1007/s00125-002-0879-5

• Immunogenicity of interferon-? in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration

  Annals of Neurology · 2000 · https://doi.org/10.1002/1531-8249(200011)48:5<706::aid-ana3>3.0.co;2-v

• Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

  The American Journal of Cardiology · 1999 · https://doi.org/10.1016/s0002-9149(98)00872-8

• Cytokines suppress human islet function irrespective of their effects on nitric oxide generation.

  Journal of Clinical Investigation · 1994 · https://doi.org/10.1172/jci117188

• 1,25-dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level

  Cytokine · 1992 · https://doi.org/10.1016/1043-4666(92)90012-g

• Interleukin-lβ-Induced Nitric Oxide Production in Isolated Rat Pancreatic Islets Requires Gene Transcription and May Lead to Inhibition of the Krebs Cycle Enzyme Aconitase*

  Endocrinology · 1991 · https://doi.org/10.1210/endo-129-6-3167

• Autoantibodies to cytokines - friends or foes?

  Immunology Today · 1990 · https://doi.org/10.1016/0167-5699(90)90068-k

• Immunohistological detection of interleukin 1-like molecules and tumour necrosis factor in human epidermis before and after UVB-irradiation in vivo

  British Journal of Dermatology · 1988 · https://doi.org/10.1111/j.1365-2133.1988.tb02430.x

• Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity

  Immunology Letters · 1988 · https://doi.org/10.1016/0165-2478(88)90141-1

• Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity.

  The Journal of Immunology · 1987 · https://doi.org/10.4049/jimmunol.139.12.4077

• Affinity-purified human Interleukin I is cytotoxic to isolated islets of Langerhans

  Diabetologia · 1986 · https://doi.org/10.1007/bf02427283

• Cytotoxicity of Human p I 7 Interleukin-1 for Pancreatic Islets of Langerhans

  Science · 1986 · https://doi.org/10.1126/science.3086977

• Cytokines Cause Functional and Structural Damage to Isolated Islets of Langerhans

  Allergy · 1985 · https://doi.org/10.1111/j.1398-9995.1985.tb02681.x

• Mediators of Immunity: Lymphokines and Monokines

  Advances in immunology · 1980 · https://doi.org/10.1016/s0065-2776(08)60043-7

Current projects

No projects listed.